

FACT SHEET

Imbruvica

DRUG INFORMATION

- **FDA Approval:** 11 total indications. Major disease indications are B cell cancers, including types of lymphoma (2013) and leukemia (2014)
- **Company:** AbbVie
- **Drug Type:** Small molecule
- **On the U.S. Market since:** 2013
- **Generic/Biosimilar approved by FDA:** No

PRICING

- **Annual List Price:** \$163,000¹
- **Price Trend:** 42% increase in the past six years²
- **Annual Medicare Spending:** \$85,128³
- **Increase in Average Spend per Medicare Beneficiary (2014-2018):** 97%
- **Annual Medicaid Spending:** \$86,647,782
- **Medicare Spending Rank:** 9th
- **Forecast:** By 2024, projected to become the fourth highest grossing drug in the U.S., with annual revenues of nearly \$9 billion⁴

PATENT LANDSCAPE

- **First Patent Filed:** 2006
- **Total Patent Applications:** 165
- **Patents Issued:** 88
- **Filed After FDA Approval:** 55%
- **Duration of Patent Protection:** 29 years (Dec 2006 - Mar 2036)

DELAYED COMPETITION IN THE U.S.

Patents on the additional conditions Imbruvica can be used to treat and how the drug is taken (e.g. a tablet or a capsule) were filed later in Imbruvica's patent lifecycle, and therefore extend commercial exclusivity more than nine years beyond the expiration of the initial patent. During that time, Americans will spend an estimated \$41 billion on branded Imbruvica.⁴

DID YOU KNOW?

Imbruvica is an example of a drug that was patented using a "drip feed" strategy. This is when drugmakers strategically space out patent filings in order to maximize the duration of their monopoly.

NOVEMBER 2020 | i-mak.org

VISIT I-MAK.ORG/IMBRUVICA

¹For the most widely used 140mg oral capsule, 90 capsule (one-month supply). <https://www.drugs.com/price-guide/imbruvica> / ²Based on AWP for 140mg capsule, 120 per package, from Jan 1, 2014 to Jan 1, 2020 / ³2018, most recent year available for all Medicare and Medicaid data / ⁴EvaluatePharma World Preview Report. Table 14: Top 10 Selling Products in the USA in 2024. May, 2019. / ⁵This calculation is based on granted patents identified as of November 2019. We anticipate that more patents will be filed and granted on this drug.